ATRS News and Press, Antares Pharma Inc. From 03/29/22

The commercial-stage pharma company, Antares Pharma (NASDAQ:ATRS), announced that the U.S. Food and Drug Administration (FDA) granted the final approval for TLANDO (testosterone undecanoate). An oral form of testosterone replacement therapy, TLANDO, is indicated for adults with hypogonadism, ...

EWING, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration granted final approval for TLANDO™ (testosterone undecanoate), an oral tre...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

The following slide deck was published by Antares Pharma, Inc. in conjunction with this event. For further details see: Antares Pharma (ATRS) Investor Presentation - Slideshow

Antares Pharma, Inc. (ATRS) Q4 2021 Earnings Conference Call March 03, 2022, 08:30 AM ET Company Participants Tram Bui - VP-Corporate Communications and IR Bob Apple - President and CEO Joe Renda - SVP-Commercial Peter Richardson - EVP -Research and Development and Chief Medical Officer Fred ...

The following slide deck was published by Antares Pharma, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Antares Pharma, Inc. 2021 Q4 - Results - Earnings Call Presentation

Gainers: DBV Technologies (NASDAQ:DBVT) +16%. EyePoint Pharmaceuticals (NASDAQ:EYPT) +14%. Antares Pharma (NASDAQ:ATRS) +10%. Nuvalent (NASDAQ:NUVL) +8%. Aquestive Therapeutics (NASDAQ:AQST) +7%. Losers: NuCana (NASDAQ:NCNA) -54%. MediWound (NASDAQ:MDWD) -15%.&#x...

Antares Pharma press release (NASDAQ:ATRS): Q4 Non-GAAP EPS of $0.02 beats by $0.01. Revenue of $48.73M (+10.5% Y/Y) beats by $1.54M. The Company today provided its full-year 2022 revenue guidance range of $200 to $220 million, which does not include any unapproved products and assumes no sig...

Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million Full-Year 2021 Net Income of $46.3 Million, or $0.26 Per Diluted Earnings Per Share Full-Year 2021 Adjusted EBITDA of $39.2 Million 2022 Revenue Guidance Range of $200 to $220 Million EWI...

Antares Pharma (NASDAQ:ATRS) is scheduled to announce Q4 earnings results on Thursday, Mar. 3, before market open. The consensus EPS estimate is $0.01 and the consensus revenue estimate is $47.19M (+7% Y/Y). Over the last 2 years, ATRS has beaten EPS estimates 75% of the time and has bea...